Walling, David

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Haight, B. R., Learned, S. M., Laffont, C. M., Fudala, P. J., Zhao, Y., Garofalo, A. S., Greenwald, M. K., Nadipelli, V. R., Ling, W., Heidbreder, C., et al. (2019) · The Lancet

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 285

Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia

Green, M. F., Schooler, N. R., Kern, R. S., Frese, F. J., Granberry, W., Harvey, P. D., Karson, C. N., Peters, N., Stewart, M., Seidman, L. J., et al. (2011) · American Journal of Psychiatry

Schizophrenia research and treatmentPsychological Testing and Assessment

Cited by 159

Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 151

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia

Hard, M. L., Wehr, A. Y., Du, Y., Weiden, P. J., Walling, D., & von Moltke, L. (2018) · Journal of Clinical Psychopharmacology

Schizophrenia research and treatmentPharmaceutical studies and practices

Cited by 17